StockCIK 1815442
Kymera Therapeutics, Inc. (KYMR): Insider Trades and Fund Holdings
In the past 12 months, Kymera Therapeutics, Inc. insiders reported 0 open-market purchases worth $0 and 2 sales worth $4.16M; 1 of the sales were reported as made under a 10b5-1 trading plan.
0Insider buys, 12 months
$0Bought by insiders, 12 months
$4.16MSold by insiders, 12 months
0Tracked funds holding
Recent insider trades
Open-market purchases (code P) and sales (code S) from Form 4. Grants, option exercises and gifts are not shown. Latest filing: Oct 1, 2026.
| Filed | Insider | Type | Value |
|---|---|---|---|
| Oct 1 | Nello MainolfiCEO | ▼ SELL10b5-1 | $3.41M |
| Sep 4 | Brian AdamsGeneral Counsel | ▼ SELL | $744K |
Source: SEC Form 4 filings, retrieved Oct 28, 2026. How we read filings
Insiders who traded in the past year
| Insider | Role | Buys | Bought | Sells | Sold |
|---|---|---|---|---|---|
| Nello Mainolfi | CEO | 0 | $0 | 1 | $3.41M |
| Brian Adams | General Counsel | 0 | $0 | 1 | $744K |
ADVERTISEMENT
320 × 100 ad slot
Reading these numbers
Insiders sell for many reasons: taxes, diversification, a house. Purchases with their own money are rarer and are usually read as more informative. A Form 4 is due within two business days of the trade. How to read a Form 4 →